

Clinical trials of extended nadroparin

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---|
| extended nadroparin vs standard treatment | | | |
| Lopez Beret , 2001 n=NA follow-up: 12 months | Nadroparin 1.025 antiXa IU/10Kg twice daily after aadroparin 1.025AXa IU/10Kg twice daily for 3 days. After 3 months, nadroparin was switched to once daily versus acenocoumarol (target INR 2-3) for 3-6 months after nadroparin 1.025AXa IU/10Kg twice daily for 3 days | patients with known malignancy treated for symptomatic DVT of the lower limb | Parallel groups outcome assessment blinded |

More details and results :

- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>

References

Lopez Beret, 2001:

Lpez-Beret P, Orgaz A, Fontcuberta J, Doblaz M, Martinez A, Lozano G, Romero A Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001;33:77-90 [[11137927](#)]

Entry terms: nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216,